Journal
VISCERAL MEDICINE
Volume 32, Issue 5, Pages 347-351Publisher
KARGER
DOI: 10.1159/000450904
Keywords
Metabolic syndrome; Appetite; Weight loss; GLP-1 analogs
Categories
Ask authors/readers for more resources
The metabolic syndrome (MS) comprises a cluster of metabolic disturbances including obesity, hyperglycemia, dyslipidemia, and elevated blood pressure that are patho-physiologically highly interlinked and that altogether lead to an increased cardiovascular (CV) risk. While lifestyle interventions represent the basic therapeutic measure to address all components of the MS, they are in most cases not effective enough to reduce the CV risk. Therefore, pharmacological interventions are necessary for many patients. This review will provide an overview on current and potential future pharmacological interventions for obesity, which is the main driver of the MS. (C) 2016 S. Karger GmbH, Freiburg
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available